Press Releases

InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study

Published: November 17, 2016

CAMBRIDGE, Mass. (Nov 17, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and  Neurologic Recovery in  Subjects with  Complete Thoracic AIS A Spinal Cord Injury) at Oregon Health & Science University (OHSU) in Portland, Oregon. Ahmed M. Raslan, M.D. and Jason J Chang, M.D.,  Assistant  Professors  of  Neurological  Surgery  and  study  investigators, performed surgery and the implantation on the T9  neurologically  complete  patient  approximately  36 hours after the injury occurred. Mark Perrin, InVivo’s Chief Executive Officer and […]

View Article
InVivo Therapeutics to Present at Neuroscience 2016

Published: November 10, 2016

CAMBRIDGE, Mass. (Nov 10, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) will present data from its ongoing nonclinical study of Neuro-Spinal Scaffold™implantation at Neuroscience 2016, the Society for Neuroscience 46th annual conference November 12-16 in San Diego. The company’s oral presentation entitled “The Neuro-Spinal Scaffold promotes tissue remodeling, axonal sprouting, and Schwann cell myelination following acute spinal cord contusion injury in rats” will be presented by Simon Moore, Ph.D., Director of Research on Monday, November 14 at 2:15 PM (PST) during the Brain and Spinal Cord Injury nanosymposium. “I look forward to sharing these latest Neuro-Spinal Scaffold nonclinical findings with the […]

View Article
InVivo Therapeutics Announces University of Iowa Hospitals and Clinics as New Site for INSPIRE Study

Published: November 9, 2016

CAMBRIDGE, Mass. (Nov 9, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that University of Iowa Hospitals and Clinics in Iowa City, IA, has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. UI Hospitals and Clinics is a 732- bed hospital which, in fiscal year 2015, received more than 57,000 emergency room visits. “Two active areas of spinal cord injury research involve timing and the use of biomaterials. The INSPIRE study represents the […]

View Article
InVivo Therapeutics Reports 2016 Third Quarter Financial Results and Business Update

Published: November 4, 2016

CAMBRIDGE, Mass. (Nov 4, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended September 30, 2016. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the third quarter, we continued to make fundamental progress at InVivo. One of the most notable achievements was the expansion of the INSPIRE study to allow for twenty evaluable patients. Just a few weeks later, we had a fifth patient improve from complete to incomplete paralysis making our current conversion rate approximately four times the rate in natural history databases (62.5% vs. 16%). Due in large part to […]

View Article
InVivo Therapeutics Announces Allegheny General Hospital as New Site for INSPIRE Study

Published: November 3, 2016

CAMBRIDGE, Mass. (Nov 3, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Allegheny General Hospital (AGH) in Pittsburgh, PA, part of Allegheny Health Network, has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Surgeries will be performed at AGH, which treats more than 24,000 inpatients each year. AGH was the first hospital in the region to receive designation as a Level I Shock Trauma Center, which is the highest designation available. “My […]

View Article
InVivo Therapeutics Announces Appointment of Jeffrey Hatfield to Board of Directors

Published: November 2, 2016

CAMBRIDGE, Mass. (Nov 2, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Jeffrey Hatfield to its Board of Directors. Mr. Hatfield most recently served as President, Chief Executive Officer, and Board Member for Vitae Pharmaceuticals and served in those capacities since joining the company in March 2004. Mr. Hatfield funded the company privately from 2005 to 2014 via three separate partnering transactions and took Vitae Pharmaceuticals public in 2014. On September 14, 2016, Allergan Plc announced that it had entered into a definitive agreement to purchase Vitae Pharmaceuticals for approximately $639 million in cash. Prior to […]

View Article
InVivo Therapeutics to Present at Upcoming Science and Advocacy Meetings

Published: October 24, 2016

- Alex Aimetti, Ph.D., Sr. Director, Medical Education and Scientific Support, to Present at Biomaterials Science and Working 2 Walk Symposia – CAMBRIDGE, Mass. (Oct 24, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will present at two upcoming science and advocacy meetings. Alex Aimetti, Ph.D., Sr. Director, Medical Education and Scientific Support, is scheduled to present a keynote presentation in Neuro Engineering at the 2016 Symposium on Biomaterials Science in Iselin, NJ on Tuesday, October 25 at 11:10 AM EDT. The symposium is hosted by the New Jersey Center for Biomaterials. Additional information can be […]

View Article
InVivo Therapeutics Announces Beth Israel Deaconess Medical Center as New Site for INSPIRE Study

Published: October 20, 2016

CAMBRIDGE, Mass. (Oct 20, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. A teaching hospital of Harvard Medical School, BIDMC consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. “We see many patients with spinal cord injuries, which makes us a great candidate for the INSPIRE study. There is […]

View Article
InVivo Therapeutics Announces Foothills Medical Centre in Calgary, Alberta as New Canadian Site for INSPIRE Study

Published: October 19, 2016

Institution is One of the Busiest Level I Trauma Centers in Canada CAMBRIDGE, Mass. (Oct 19, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Foothills Medical Centre in Calgary, Alberta has been added as a Canadian clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Foothills Medical Centre is the largest hospital in Alberta and is one of the most recognized medical facilities in Canada, providing advanced healthcare services to over two million people from Calgary […]

View Article
InVivo Therapeutics to Present at Cell & Gene Meeting on the Mesa

Published: September 26, 2016

CAMBRIDGE, Mass. (Sept 26, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla, California. The company’s presentation will be on October 6 at 4:00 PM (PDT). A live webcast will be available at http://www.meetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine (ARM)’s website shortly after the event. Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.